OBJECTIVES: Cigarette smoking behavior in bipolar disorder (BPD), including the effects of mood-stabilizing medications, has not been well characterized. METHODS: We compared serum nicotine, nicotine metabolite levels, and smoking topography in 75 smokers with BPD to 86 control smokers (CON). For some comparisons, an additional control group of 75 smokers with schizophrenia (SCZ) were included. RESULTS: There were no differences between the BPD and CON groups in baseline smoking characteristics or serum nicotine or cotinine levels. Fifty-one smokers with BPD (68.9%) were taking one of the following mood stabilizers: valproic acid, lamotrigine, carbamazepine, oxcarbazepine, lithium, or topiramate. The 3-hydroxycotinine-to-cotinine ratio, a marker of cytochrome P450 2A6 (CYP2A6) metabolic activity, was significantly higher in BPD versus CON and versus SCZ (0.68 versus 0.49 versus 0.54; p =0.002). The difference between groups, however, was no longer significant when the analysis was repeated with those taking hepatic enzyme-inducing drugs (carbamazepine, oxcarbazepine, and topiramate) included as a covariate. The time between puffs, or interpuff interval (IPI), was shorter in BPD versus CON by an average of 3.0sec (p<0.05), although this was no longer significant when we removed smokers from the analysis of those taking hepatic enzyme inducers. CONCLUSIONS: Smokers with BPD are not different from CON on most measures of nicotine intake and smoking topography. We found an increased rate of nicotine metabolism in smokers taking mood stabilizers that are hepatic enzyme inducers, including carbamazepine, oxcarbazepine, and topiramate. Smokers with rapid nicotine metabolism might be expected to smoke more intensely to compensate for the more rapid disappearance of nicotine from the blood and brain, and may have more difficulty in quitting smoking, although this requires further study.
OBJECTIVES: Cigarette smoking behavior in bipolar disorder (BPD), including the effects of mood-stabilizing medications, has not been well characterized. METHODS: We compared serum nicotine, nicotine metabolite levels, and smoking topography in 75 smokers with BPD to 86 control smokers (CON). For some comparisons, an additional control group of 75 smokers with schizophrenia (SCZ) were included. RESULTS: There were no differences between the BPD and CON groups in baseline smoking characteristics or serum nicotine or cotinine levels. Fifty-one smokers with BPD (68.9%) were taking one of the following mood stabilizers: valproic acid, lamotrigine, carbamazepine, oxcarbazepine, lithium, or topiramate. The 3-hydroxycotinine-to-cotinine ratio, a marker of cytochrome P450 2A6 (CYP2A6) metabolic activity, was significantly higher in BPD versus CON and versus SCZ (0.68 versus 0.49 versus 0.54; p =0.002). The difference between groups, however, was no longer significant when the analysis was repeated with those taking hepatic enzyme-inducing drugs (carbamazepine, oxcarbazepine, and topiramate) included as a covariate. The time between puffs, or interpuff interval (IPI), was shorter in BPD versus CON by an average of 3.0sec (p<0.05), although this was no longer significant when we removed smokers from the analysis of those taking hepatic enzyme inducers. CONCLUSIONS: Smokers with BPD are not different from CON on most measures of nicotine intake and smoking topography. We found an increased rate of nicotine metabolism in smokers taking mood stabilizers that are hepatic enzyme inducers, including carbamazepine, oxcarbazepine, and topiramate. Smokers with rapid nicotine metabolism might be expected to smoke more intensely to compensate for the more rapid disappearance of nicotine from the blood and brain, and may have more difficulty in quitting smoking, although this requires further study.
Authors: Jill M Williams; Kunal K Gandhi; Shou-En Lu; Supriya Kumar; Junwu Shen; Jonathan Foulds; Howard Kipen; Neal L Benowitz Journal: Nicotine Tob Res Date: 2010-06-28 Impact factor: 4.244
Authors: Seetal Dodd; Alan J M Brnabic; Lesley Berk; Paul B Fitzgerald; Anthony R de Castella; Sacha Filia; Kate Filia; Katarina Kelin; Meg Smith; William Montgomery; Jayashri Kulkarni; Michael Berk Journal: Compr Psychiatry Date: 2010-02-19 Impact factor: 3.735
Authors: Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn E Lerman Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-06 Impact factor: 4.254
Authors: Jill M Williams; Kunal K Gandhi; Shou-En Lu; Supriya Kumar; Marc L Steinberg; Brett Cottler; Neal L Benowitz Journal: Drug Alcohol Depend Date: 2011-05-18 Impact factor: 4.492
Authors: Michael J Ostacher; Richard T Lebeau; Roy H Perlis; Andrew A Nierenberg; Hannah G Lund; Samantha J Moshier; Gary S Sachs; Naomi M Simon Journal: Bipolar Disord Date: 2009-11 Impact factor: 6.744
Authors: M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale Journal: Clin Pharmacol Ther Date: 2009-03-11 Impact factor: 6.875
Authors: Allshine Chen; Nicolle M Krebs; Junjia Zhu; Dongxiao Sun; Andrea Stennett; Joshua E Muscat Journal: J Womens Health (Larchmt) Date: 2017-09-05 Impact factor: 2.681
Authors: Nicolle M Krebs; Allshine Chen; Junjia Zhu; Dongxiao Sun; Jason Liao; Andrea L Stennett; Joshua E Muscat Journal: Am J Epidemiol Date: 2016-06-16 Impact factor: 4.897
Authors: Jaimee L Heffner; A Eden Evins; Cristina Russ; David Lawrence; Catherine R Ayers; Thomas McRae; Lisa St Aubin; Alok Krishen; Robert West; Robert M Anthenelli Journal: J Affect Disord Date: 2019-06-03 Impact factor: 4.839
Authors: Robert Schnoll; E Paul Wileyto; Anna-Marika Bauer; Erica Fox; Frank Leone; Caryn Lerman; Rachel F Tyndale; Tony P George; Larry Hawk; Paul Cinciripini; Mackenzie Quinn; Janelle Purnell; Jane Hatzell; Brian Hitsman Journal: Am J Addict Date: 2021-03-26